|
[English Session]
[Vascular] |
Apr. 19 (Fri.) 09:30-11:00 103 (1F) |
| Vascular Aging and Cardiovascular Risk Assessment |
| Panel | Sung Ae Kim, Chi Young Shim, Eun Joo Cho |
| 09:30-09:50 |
Noninvasive Assessment of Arterial Stiffness: Recent Updates
|
Si Hyuck Kang / Seoul National Univ., Korea |
| 09:50-10:10 |
Cardiovascular Risk Assessment in Asians: Challenges and Opportunities
|
Eugene Yang / Univ. of Washington, USA |
| 10:10-10:30 |
Impact of Arterial Stiffness on Cardiac Function and Outcome
|
Hack Lyoung Kim / Seoul National Univ., Korea |
| 10:30-10:50 |
Impact of Arterial Stiffness on Renal Function and Outcome
|
Chan Joo Lee / Yonsei Univ., Korea |
| 10:50-11:00 |
Discussion |
|
[Myocardial Infarction 1] |
Apr. 19 (Fri.) 09:30-11:00 106 (1F) |
| Myocardial Infarction: What's New in AMI? |
| Chairperson(s) | 채성철, 정명호 |
| Panel | 박종선, 배장환, 이장훈, 장기육, 황진용 |
| 09:30-09:45 |
A New Identifying and Classifying AMI; Case-Based Approach
|
윤혁준 / 계명의대 |
| 09:45-10:00 |
Optimizing DAPT Duration after AMI; Case-Based Approach
|
박용휘 / 경상의대 |
| 10:00-10:15 |
How to Limit Infarct Size in STEMI?
|
강현재 / 서울의대 |
| 10:15-10:30 |
Hemodynamic Support: Which Device for Which Patient and Why?
|
장우진 / 이화의대 |
| 10:30-11:00 |
Discussion |
|
[Hypertension] |
Apr. 19 (Fri.) 11:10-12:40 103 (1F) |
| Resistant Hypertension |
| Chairperson(s) | 조명찬, 박창규 |
| Panel | 김원, 정우백, 조진만 |
| 11:10-11:30 |
How to Approach to Resistant Hypertension
|
임상현 / 가톨릭의대 |
| 11:30-11:50 |
How to Manage Resistant Hypertension
|
신진호 / 한양의대 |
| 11:50-12:20 |
Renal Nerve Denervation: Current and Future
|
김병극 / 연세의대 |
| 12:20-12:40 |
Discussion |
|
[Cross Specialty: Intervention & Heart Failure] |
Apr. 19 (Fri.) 11:10-12:40 104 (1F) |
| Ischemic Cardiomyopathy: Case-Based Debate & Discussion |
| Chairperson(s) | 유규형, 권현철 |
| Panel | 김수중, 송영빈, 이상엽, 이혜원, 조재영, 최의영 |
| 11:10-11:22 |
Is This Patient Ischemic Cardiomyopathy?
|
김계훈 / 전남의대 |
| 11:22-11:30 |
Discussion |
| 11:30-11:42 |
How to Evaluate the Myocardial Ischemia/Viability?
|
윤혁준 / 계명의대 |
| 11:42-11:50 |
Discussion |
| 11:50-12:02 |
What Is the Optimal Medical Therapy?
|
유병수 / 연세원주의대 |
| 12:02-12:10 |
Discussion |
| 12:10-12:22 |
If Amenable, How to Revascularize?
|
이주명 / 성균관의대 |
| 12:22-12:30 |
Discussion |
| 12:30-12:40 |
Discussion |
|
[Adult Congenital Heart Disease 1] |
Apr. 19 (Fri.) 11:10-12:40 106 (1F) |
| Lifelong Issues of Valves - How to Save the Pulmonary and Aortic Valves |
| Chairperson(s) | 현명철, 배은정 |
| Panel | 김중선, 박천수, 양지혁, 은영민, 장소익 |
| 11:10-11:25 |
Pulmonary Valve Disease in Adult
|
조익성 / 중앙의대 |
| 11:25-11:40 |
Pulmonary Valve Replacement for PS or PR with Surgery in CHD
|
이철 / 가톨릭의대 |
| 11:40-11:55 |
Pulmonary Valve Replacement for PS or PR with Transcatheter Intervention in CHD
|
최재영 / 연세의대 |
| 11:55-12:10 |
Bicuspid Aortic Valve
|
박성지 / 성균관의대 |
| 12:10-12:25 |
Aortic Valve Replacement with Transcatheter Intervention(TAVI) in Bicuspid Aortic Valve
|
홍범기 / 연세의대 |
| 12:25-12:40 |
Discussion |
|
[Women Heart Disease] |
Apr. 19 (Fri.) 11:10-12:40 201 (2F) |
| Valvular Heart Disease in Women |
| Chairperson(s) | 김명아, 홍경순 |
| Panel | 김신재, 김학령, 설상훈, 윤현주 |
| 11:10-11:30 |
Gender Difference in Mitral Valve Disease
|
손일석 / 경희의대 |
| 11:30-11:50 |
Outcomes Following Valve Surgery
|
정동섭 / 성균관의대 |
| 11:50-12:10 |
TAVI and PMV
|
장기육 / 가톨릭의대 |
| 12:10-12:30 |
Management of Valvular Disease in Pregnancy
|
박성미 / 고려의대 |
| 12:30-12:40 |
Discussion |
|
[Cardiac Pathology] |
Apr. 19 (Fri.) 11:10-12:40 203 (2F) |
| 3D Modeling, 3D Printing, Virtual Reality and Real Hearts |
| Chairperson(s) | 김성호, 정해억 |
| Panel | 배장환, 송진영, 이창하, 조구영 |
| 11:10-11:25 |
Cross the Border Between the Real and the Virtual!
|
서정욱 / 서울의대 |
| 11:25-11:40 |
The Limitation of 2D Imaging. Why Do We Need 3D Imaging and 3D Printing?
|
윤연이 / 서울의대 |
| 11:40-11:55 |
3D Patient-Specific Digital Model from CT or MRI
|
이활 / 서울의대 |
| 11:55-12:10 |
Clinical Application of 3D Printing in Congenital Heart Disease
|
송미경 / 서울의대 |
| 12:10-12:25 |
3D Printing Application in Cardiac Surgery
|
윤태진 / 울산의대 |
| 12:25-12:40 |
Discussion |
|
Scientific Session [Boryung] |
Apr. 19 (Fri.) 12:45-13:25 103 (1F) |
| Recent Results in Clinical Trials of Fimasartan in Essential Hypertension |
| Chairperson(s) | 정명호, 채인호 |
| 12:45-13:05 |
Beneficial Effect of Fimasartan in HTN Patients
|
박진주 / 서울의대 |
| 13:05-13:25 |
How to Achieve BP Control? The Answer Is Fimasartan Based SPC!
|
홍영준 / 전남의대 |
|
Scientific Session [BMS/Pfizer] |
Apr. 19 (Fri.) 12:45-13:25 104 (1F) |
| Managing AF Patient with Concomitant ACS/undergoing PCI : The AUGUSTUS Trial |
| Chairperson(s) | 김준수, 김효수 |
| 12:45-13:05 |
Antithrombotic Therapy in Patients with NVAF Undergoing PCI : Should We Change Our Practice?
|
강현재 / 서울의대 |
| 13:05-13:25 |
AUGUSTUS Trial : An Open-label, 2 x 2 Factorial, Randomized Trial to Evaluate the Safety of Apixaban vs.VKA and Aspirin vs. Placebo in Patients with AF and ACS and/or PCI
|
Renato Delascio Lopes / Duke Univ., USA |
|
Scientific Session [Samjin] |
Apr. 19 (Fri.) 12:45-13:25 106 (1F) |
| Prevention & Treatment for CardioMetabolic Syndrome |
| Chairperson(s) | 황교승, 구본권 |
| 12:45-13:05 |
Role of Clopidogrel in Coronary Artery Disease
|
김수중 / 경희의대 |
| 13:05-13:25 |
Stroke Prevention in Patients with Metabolic Syndrome and Atrial Fibrillation
|
김진석 / 고려의대 |
|
Scientific Session [MSD] |
Apr. 19 (Fri.) 12:45-13:25 201 (2F) |
| Protecting Patients with CVD in the Future |
| Chairperson(s) | 홍명기, 박헌식 |
| 12:45-13:05 |
The Benefit of Ezetimibe/atorvastantin Combination in Coronary Patients Treatment
|
정영훈 / 경상의대 |
| 13:05-13:25 |
New Treatment Option for SGLT2-Inhibitor in T2DM Patients-Ertugliflozin
|
배장환 / 충북의대 |
|
Scientific Session [Amgen] |
Apr. 19 (Fri.) 12:45-13:25 203 (2F) |
| PCSK9i (Evolocumab) : An Evolutionary Approach to Cardiovascular Therapeutics |
| Chairperson(s) | 정욱성, 김두일 |
| 12:45-13:05 |
The Positioning of PCSK9i in Updated Guidelines of Dyslipidemia
|
김병진 / 성균관의대 |
| 13:05-13:25 |
Clinical Evidence of Evolocumab and Its Practical Use
|
홍순준 / 고려의대 |
|
Diamond Session [Bayer] |
Apr. 19 (Fri.) 12:45-13:25 205 (2F) |
| Rivaroxaban, Decade of Consistency |
| Chairperson(s) | 이문형, 권현철 |
| 12:45-13:05 |
Consistent Safety Outcome of Rivaroxaban in NVAF Patients with Renal Impairment
|
최종일 / 고려의대 |
| 13:05-13:25 |
Safety Outcome of Rivaroxaban in AF Patient Undergoing PCI
|
박경우 / 서울의대 |
|
[English Session]
[Memorial Lecture] |
Apr. 19 (Fri.) 13:40-14:30 205 (2F) |
| Chairperson(s) | Kee Sik Kim |
| 13:40-14:00 |
In Memory of Hi Myung Park
|
Shung Chull Chae / Kyungpook National Univ., Korea |
| 14:00-14:20 |
Revascularization in Heart Failure: What We Now Know and Need to Still Learn
|
Eric Velaquez / Yale Univ.,USA |
| 14:20-14:30 |
Discussion |
|
[Myocardial Infarction 2] |
Apr. 19 (Fri.) 14:30-16:00 106 (1F) |
| Myocardial Infarction: Flash Debates in AMI |
| Chairperson(s) | 김종진, 차광수 |
| Panel | 김동기, 윤재용, 조진만, 허승호, 허정호 |
| 14:30-14:45 |
Fibrinolytic Therapy Versus Primary PCI in STEMI
|
심두선 / 전남의대 |
| 14:45-15:00 |
Can Beta-Blockers Be Terminated Post-MI? - Who Really Needs Them and How Long?
|
윤창환 / 서울의대 |
| 15:00-15:15 |
PCI Strategy in Multi Vessel Disease: How and When?
|
안성균 / 연세원주의대 |
| 15:15-15:30 |
Challenges in AMI: Personalized Cardiology in the Very Elderly Population
|
이상엽 / 충북의대 |
| 15:30-16:00 |
Discussion |
|
[Basic Research 1] |
Apr. 19 (Fri.) 14:30-16:00 203 (2F) |
| Understanding Basics of Cardiovascular Research, Part I |
| Chairperson(s) | 안영근, 한진 |
| Panel | 권기환, 김기석, 민필기, 이상학, 주형준, 홍순준 |
| 14:30-14:50 |
Use of Animal Models in Cardiovascular Research
|
박훈준 / 가톨릭의대 |
| 14:50-15:10 |
Non-coding RNAs in Vascular Calcification
|
국현 / 전남의대 |
| 15:10-15:30 |
The Past, Present, and Future of Adult Stem Cell Research
|
권유욱 / 서울의대 |
| 15:30-16:00 |
Discussion |
|
[Adult Congenital Heart Disease 2] |
Apr. 19 (Fri.) 16:10-17:40 106 (1F) |
| Incidentally Diagnosed Congenital Heart Disease: How to Treat and Follow-Up |
| Chairperson(s) | 박승우, 송종민 |
| Panel | 선병주, 송진영, 양동헌, 이미래 |
| 16:10-16:25 |
Atrial Septal Defect
|
강이석 / 성균관의대 |
| 16:25-16:40 |
Patent Ductus Arteriosus
|
박혁진 / 전남의대 |
| 16:40-16:55 |
Ventricular Septal Defect
|
최정현 / 부산의대 |
| 16:55-17:10 |
Anomalous Origin of Coronary Artery
|
김형관 / 서울의대 |
| 17:10-17:25 |
Persistent Foramen Ovale
|
나진오 / 고려의대 |
| 17:25-17:40 |
Discussion |
|
[Cardiac Surgery] |
Apr. 19 (Fri.) 16:10-17:40 201 (2F) |
| Understanding the Valve Surgeries for Cardiologists - Surgical Video Session |
| Chairperson(s) | 나찬영, 조광조 |
| Panel | 김준성, 송승환, 신성호, 이해영, 홍준화 |
| 16:10-16:25 |
Cardiopulmonary Bypass Setup and Aortic Valve Replacement
|
박표원 / 성균관의대 |
| 16:25-16:35 |
Sutureless Aortic Valve Replacement
|
김경환 / 서울의대 |
| 16:35-16:45 |
Minimally Invasive Valve Surgery
|
제형곤 / 부산의대 |
| 16:45-16:55 |
Replacement of the Aortic Root (Bentall)
|
주현철 / 연세의대 |
| 16:55-17:05 |
Reimplantation of the Aortic Root (David)
|
주석중 / 울산의대 |
| 17:05-17:15 |
Totally Endoscopic Redo Mitral and Tricuspid Valve Surgery
|
유재석 / 세종병원 |
| 17:15-17:40 |
Discussion |
|
[Basic Research 2] |
Apr. 19 (Fri.) 16:10-17:40 203 (2F) |
| Understanding Basics of Cardiovascular Research, Part II |
| Chairperson(s) | 오구택, 최동훈 |
| Panel | 기해진, 김용숙, 엄광현, 이찬주, 장우철, 허진 |
| 16:10-16:30 |
Practical Experience with Electrocardiography in Mouse
|
최종일 / 고려의대 |
| 16:30-16:50 |
Translational Research on Vaso-proliferative Retinopathy Using in Vivo Genome Editing
|
김정훈 / 서울의대 |
| 16:50-17:10 |
Understanding of Endothelial Mechanotransduction for Basic Researchers
|
우창훈 / 영남의대 |
| 17:10-17:40 |
Discussion |
|
[Ethics Workshop] |
Apr. 19 (Fri.) 16:10-17:40 205 (2F) |
| 늘어나는 의료분쟁과 의료현장에서 의료인폭행, 어떻게 이해할것인가? |
| Chairperson(s) | 김영대, 신동구 |
| Panel | 김형윤, 심지영, 황경국 |
| 16:10-16:30 |
의료분쟁의 현황과 원인
|
이동학 / 한국의료분쟁조정중재원 |
| 16:30-16:50 |
의료분쟁(사고)의 올바른 이해와 예방
|
윤태중 / 법무법인 태신 |
| 16:50-17:10 |
의료현장에서의 의료인에 대한 폭언과 폭행: 의료윤리적 대책
|
구영모 / 울산의대 |
| 17:10-17:30 |
임상윤리의 이해
|
권복규 / 이화의대 |
| 17:30-17:40 |
Discussion |
|
[Imaging] |
Apr. 20 (Sat.) 09:00-10:30 103 (1F) |
| Imaging of Stable Coronary Artery Disease |
| Chairperson(s) | 송재관, 정정임 |
| 09:00-09:20 |
Diagnostic Approach of Stable Coronary Artery Disease
|
안정민 / 울산의대 |
| 09:20-09:40 |
Update of Cardiac CT for Stable Coronary Artery Disease
|
전은주 / 서울의대 |
| 09:40-10:00 |
CMR Perfusion and Viability
|
장성아 / 성균관의대 |
| 10:00-10:20 |
PET and Hybrid Imaging
|
강원준 / 연세의대 |
| 10:20-10:30 |
Discussion |
|
[Smart Health] |
Apr. 20 (Sat.) 09:00-10:30 203 (2F) |
| Digital Cardiology Transformation |
| Chairperson(s) | 김용진, 김영학 |
| Panel | 김형섭, 박경우, 배장환 |
| 09:00-09:20 |
Potential Application of Brain-Computer Interface for Communication and Rehabiliation
|
임창환 / 한양대학교 |
| 09:20-09:40 |
노인 및 뇌졸중 환자의 보행 보조로봇
|
김연희 / 성균관의대 |
| 09:40-10:00 |
Multicenter Atrial Fibrillation Registry Study Using Common Data Model
|
조민수 / 울산의대 |
| 10:00-10:20 |
Global Digital Healthcare Service Development
|
김영인 / Noom코리아㈜ |
| 10:20-10:30 |
Discussion |
|
[Cross Specialty: Arrhythmia & Heart Failure] |
Apr. 20 (Sat.) 09:00-09:45 205 (2F) |
| Debate 1: Primary Prevention ICDs in Patients with EF ≥ 35% |
| Chairperson(s) | 최동주, 오용석 |
| Panel | 백용수, 유희태, 정욱진, 최성훈 |
| 09:00-09:15 |
Pro.
|
박승정 / 성균관의대 |
| 09:15-09:30 |
Con.
|
박진주 / 서울의대 |
| 09:30-09:45 |
Discussion |
|
[Cross Specialty: Arrhythmia & Heart Failure] |
Apr. 20 (Sat.) 09:45-10:30 205 (2F) |
| Debate 2: Atrial Fibrillation Ablation in Patients with Heart Failure |
| Chairperson(s) | 최동주, 오용석 |
| Panel | 양동헌, 유승기, 이소령, 이영수 |
| 09:45-10:00 |
Pro.
|
엄재선 / 연세의대 |
| 10:00-10:15 |
Con.
|
김인철 / 계명의대 |
| 10:15-10:30 |
Discussion |
|
[Healthcare Policy] |
Apr. 20 (Sat.) 10:40-12:10 103 (1F) |
| 심장질환 급성기 치료 관련 전문인력 적정화 방안 |
| Chairperson(s) | 김기식, 김병옥 |
| Panel | 배장환, 안철민, 조덕규 |
| 10:40-10:55 |
전공의 수련특별법이 임상에 미치는 영향
|
장성인 / 연세의대 |
| 10:55-11:10 |
주 52시간 근로기준법 적용이 심혈관응급진료에 미치는 영향
|
문건웅 / 가톨릭의대 |
| 11:10-11:25 |
Hospitalist, 의료인력 공백의 현실적 대안인가?
|
김영삼 / 연세의대 |
| 11:25-12:10 |
Discussion |
|
[Cross Specialty: Intervention & Imaging] |
Apr. 20 (Sat.) 10:40-12:10 104 (1F) |
| Beyond TAVR- Percutaneous Intervention in MV and TV |
| Chairperson(s) | 박승정, 최병욱 |
| Panel | 고영국, 김주한, 김형관, 손일석, 용환석 |
| 10:40-10:52 |
Recent Update in TAVR 2019: Interventionist Perspective
|
김효수 / 서울의대 |
| 10:52-11:04 |
Recent Update in TAVR 2019: Imaging Specialist Perspective
|
정정임 / 가톨릭의대 |
| 11:04-11:19 |
Discussion |
| 11:19-11:31 |
Time to Start in Korea
|
박덕우 / 울산의대 |
| 11:31-11:43 |
ECHO Planning
|
홍그루 / 연세의대 |
| 11:43-11:55 |
CT Planning
|
양동현 / 울산의대 |
| 11:55-12:10 |
Discussion |
|
Scientific Session [Hanmi] |
Apr. 20 (Sat.) 12:15-12:55 103 (1F) |
| New Insight on Intensive Treatment for Hypertension and Dyslipidemia Management |
| Chairperson(s) | 박창규, 최동훈 |
| 12:15-12:35 |
Evidence-based Approach for Ideal Hypertension Management
|
조구영 / 서울의대 |
| 12:35-12:55 |
Advantages of Rosuvastatin and Ezetimibe Combination Treatment
|
이무용 / 동국의대 |
|
Scientific Session [Bayer] |
Apr. 20 (Sat.) 12:15-12:55 104 (1F) |
| Tailored Protection for Your Cardio-vascular Patients |
| Chairperson(s) | 김기식, 오용석 |
| 12:15-12:35 |
Consideration of Renal Outcome in Anticoagulation Treatment in NVAF Patients with Renal Impairment
|
임홍의 / 한림의대 |
| 12:35-12:55 |
New Antithrombotic Treatment Strategies in Patients with Chronic CAD and PAD
|
김병극 / 연세의대 |
|
Scientific Session [Takeda/Dong-A ST] |
Apr. 20 (Sat.) 12:15-12:55 106 (1F) |
| The Way to Improve BP Control Rate |
| Chairperson(s) | 김철호, 조명찬 |
| 12:15-12:35 |
Differential Benefits and Real World Clinical Practices of Azilsartan Medoxomil
|
홍그루 / 연세의대 |
| 12:35-12:55 |
The 1st APC, Azilsartan Medoxomil/Chlorthalidone for Uncontrolled Hypertensive Patients
|
김용진 / 서울의대 |
|
Scientific Session [Novartis] |
Apr. 20 (Sat.) 12:15-12:55 201 (2F) |
| ARNI : PIONEER HF for Hospitalized Patients |
| Chairperson(s) | 전은석, 최동주 |
| 12:15-12:55 |
PIONEER-HF : Prime Time for ARNI in Stabilized AHF Patients
|
Eric Velaquez / Yale Univ.,USA |
|
Scientific Session [Daiichisankyo/ Daewoong] |
Apr. 20 (Sat.) 12:15-12:55 203 (2F) |
| Achieving Best Outcomes for Patients with Cardiovascular Disease with Edoxaban and Olmesartan |
| Chairperson(s) | 강석민, 편욱범 |
| 12:15-12:35 |
Translating RWE: Validating Safety and Effetiveness of NOACs in Clinical Tractice
|
최의근 / 서울의대 |
| 12:35-12:55 |
New Strategies to Improve Treatment Adherence in Hypertension
|
성지동 / 성균관의대 |
|
Diamond Session [BMS/Pfizer] |
Apr. 20 (Sat.) 12:15-12:55 205 (2F) |
| Leading Excellence for Stroke Prevention in NVAF |
| Chairperson(s) | 한성욱, 정보영 |
| 12:15-12:35 |
AUGUSTUS Trial : What Is the Optimal Antithrombotic Strategy for AF Patient Who Develop ACS
|
Renato Delascio Lopes / Duke Univ., USA |
| 12:35-12:55 |
Anticoagulation in AF with Comorbidities: “Fragile Patient”
|
배명환 / 경북의대 |
|
Scientific Session [Pfizer] |
Apr. 20 (Sat.) 12:15-12:55 211 (2F) |
| Strategies to Optimize Management of CVD |
| Chairperson(s) | 김영대 |
| 12:15-12:35 |
Highlighting 20 Years of CV Protection with Atorvastatin : Focusing on Secondary Prevention
|
남창욱 / 계명의대 |
| 12:35-12:55 |
Blood Pressure Variability : Its Prognostic Significance in CV Disease
|
손일석 / 경희의대 |
|
[Epidemiology] |
Apr. 20 (Sat.) 14:50-16:20 201 (2F) |
| Novel Biomarkers and Risk Factors for Heart Disease |
| Chairperson(s) | 김광일, 김현창 |
| Panel | 배장환, 손일석, 정선재 |
| 14:50-15:00 |
Systems Epidemiology Approach for Better CVD Prevention
|
김현창 / 연세의대 |
| 15:00-15:15 |
Stress Biomarkers and Cardiovascular Disease
|
이주미 / 을지의대 |
| 15:15-15:30 |
Immunosenescence & Inflammaing Biomarkers and Cardiovascular Disease
|
이원우 / 서울의대 |
| 15:30-15:45 |
Mebabolomics Approach to Biomarkers and Mechanisms of Cardiometabolic Disease
|
이상국 / 연세의대 |
| 15:45-16:00 |
Social Network Analysis and Cardiovascular Disease
|
염유식 / 연세대학교 |
| 16:00-16:20 |
Discussion |
대한심장학회
대한부정맥학회
대한소아심장학회
대한심부전학회
대한심혈관중재학회
순환기의공학회
심장대사증후군학회
한국심초음파학회
한국지질·동맥경화학회